JAGX vs. QTTB, ANVS, TPST, ITRM, ANEB, CASI, CLNN, OKYO, CALC, and ELEV
Should you be buying Jaguar Health stock or one of its competitors? The main competitors of Jaguar Health include Q32 Bio (QTTB), Annovis Bio (ANVS), Tempest Therapeutics (TPST), Iterum Therapeutics (ITRM), Anebulo Pharmaceuticals (ANEB), CASI Pharmaceuticals (CASI), Clene (CLNN), OKYO Pharma (OKYO), CalciMedica (CALC), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry.
Jaguar Health vs.
Jaguar Health (NASDAQ:JAGX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
Jaguar Health has higher revenue and earnings than Q32 Bio.
Q32 Bio has a consensus target price of $24.86, indicating a potential upside of 867.20%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Jaguar Health.
Jaguar Health has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500.
Q32 Bio has a net margin of 0.00% compared to Jaguar Health's net margin of -360.13%. Q32 Bio's return on equity of -146.18% beat Jaguar Health's return on equity.
12.0% of Jaguar Health shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 0.0% of Jaguar Health shares are owned by company insiders. Comparatively, 16.1% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Jaguar Health had 3 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for Jaguar Health and 0 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.79 beat Jaguar Health's score of 0.10 indicating that Q32 Bio is being referred to more favorably in the news media.
Jaguar Health received 1823 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 88.73% of users gave Jaguar Health an outperform vote while only 66.67% of users gave Q32 Bio an outperform vote.
Summary
Q32 Bio beats Jaguar Health on 10 of the 16 factors compared between the two stocks.
Get Jaguar Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Health Competitors List
Related Companies and Tools
This page (NASDAQ:JAGX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free JAGX Stock Alerts